{"": [104, 2158, 0], "1 Introduction for Pharmacogenetics of COVID-19 Treatment": [2159, 7669, 0], "2 Virology of SARS-CoV-2 and its Entry Into Human Cells": [7670, 11140, 0], "3 Immune Response, Pathogenesis, and Clinical Manifestation of COVID-19": [11141, 17234, 0], "4 Treatments of COVID-19": [17235, 18236, 0], "5 Repurposing Drugs for COVID-19: Concept and Mechanism of Action": [18237, 29535, 0], "6.1 Anticoagulants": [29592, 30395, 0], "6.2 Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers": [30396, 31435, 0], "6.3 Antiplatelets": [31436, 32053, 0], "6.4 Antifibrotics": [32054, 32522, 0], "6.5 Systemic Corticosteroids": [32523, 34578, 0], "6.6 Bronchodilators/Vasodilators": [34579, 35199, 0], "6.7 Non-Steroidal Anti-Inflammatory Drugs": [35200, 35726, 0], "6 Potential Risk of COVID-19 and Supportive Treatments": [29536, 35726, 1], "7 Pharmacogenomics and Precision Medicine for COVID-19": [35727, 36787, 0], "8.1.1 Drug-Metabolizing Enzymes": [36916, 38447, 0], "8.1.2 Transporters": [38448, 39138, 0], "8.1 Genetic Variants Affecting the Safety or Efficacy of COVID-19 Therapies": [36839, 39138, 1], "8.2.1 HLA\n": [39203, 45922, 0], "8.2.2 ACE2\n": [45923, 47137, 0], "8.2.3 TMPRSS2\n": [47138, 47656, 0], "8.2 Other Genes Affecting the Severity of SARS-CoV-2 Infection": [39139, 47656, 1], "8 Pharmacogenomic Landscape of COVID-19 Therapies": [36788, 47656, 1], "9.1.1 Ivermectin": [47945, 48668, 0], "9.1 Antiparasitics": [47755, 48668, 1], "9.2.1 Remdesivir": [48690, 51182, 0], "9.2.2 Ribavirin": [51183, 53806, 0], "9.2.3 Favipiravir": [53807, 54996, 0], "9.2.4 Oseltamivir": [54997, 55567, 0], "9.2.5 Nevirapine": [55568, 55955, 0], "9.2 Antiviral Drugs": [48669, 55955, 1], "9.3.1 Lopinavir/Ritonavir": [55983, 57596, 0], "9.3.2 Darunavir/Cobicistat": [57597, 58341, 0], "9.3.3 Atazanavir": [58342, 59441, 0], "9.3.4 Efavirenz": [59442, 60356, 0], "9.3 Antiretroviral Agents": [55956, 60356, 1], "9.4 Interferon \u03b2-1b": [60357, 60966, 0], "9.5 IL-6 and IL-1 Antagonists": [60967, 62137, 0], "9.6 Inhibitors of the Renin Angiotensin Aldosterone System": [62138, 62850, 0], "9.7 Janus Kinase Inhibitors": [62851, 63356, 0], "9.8 Antibiotics": [63357, 64008, 0], "9.9 Corticosteroids": [64009, 64824, 0], "9.10 Antiplatelets": [64825, 66406, 0], "9.11 Anticoagulants": [66407, 67139, 0], "9.12 Non-Steroidal Anti-inflammatory Drugs": [67140, 68348, 0], "9 Pharmacogenetics Considerations of COVID-19 Therapeutics: Implications for Efficacy and Safety": [47657, 68348, 1], "10.1 Spike Protein": [69075, 72392, 0], "10.2.1 Main Protease": [73727, 77268, 0], "10.2.2 Papain-Like Protease": [77269, 79626, 0], "10.2 Proteases": [72393, 79626, 1], "10.4 RNA-Dependent RNA Polymerase": [79627, 82873, 0], "10 In Silico Prediction of Drug Effects in Treatments for COVID-19": [68349, 82873, 1], "11 Pharmacogenomics for COVID-19 Vaccine": [82874, 86881, 0], "12.1 Drug\u2013Drug Interactions": [86957, 89311, 0], "12.2 Patients\u2019 Condition and Underlying Diseases": [89312, 91738, 0], "12.3 Drug\u2013Herb Interactions": [91739, 96003, 0], "12 Precision Medicine for COVID-19 Treatment: Key Clinical Considerations": [86882, 96003, 1], "13.1.1 Mandate Genetic Test for COVID-19 Severity": [96553, 96814, 0], "13.1.2 Mandate Theranostics": [96815, 97936, 0], "13.1 Mandate Genetic Test": [96526, 97936, 1], "13.2 Recommendations for Theranostics": [97937, 99729, 0], "13 Genetic Testing for COVID-19 Treatment: Panel of Gene Considerations": [96004, 99729, 1], "14 Pharmacogenomics and Precision Medicine for COVID-19 in Thailand": [99730, 101305, 0], "15 Clinical Perspective": [101306, 103000, 0], "16 Conclusion": [103001, 105538, 0]}